<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609531</url>
  </required_header>
  <id_info>
    <org_study_id>04-0975</org_study_id>
    <secondary_id>NIH/NCRR K12 RR023248</secondary_id>
    <secondary_id>The Dana Foundation</secondary_id>
    <secondary_id>K23MH081285</secondary_id>
    <nct_id>NCT00609531</nct_id>
  </id_info>
  <brief_title>Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders</brief_title>
  <official_title>Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proof of concept study is to use functional magnetic resonance imaging&#xD;
      and behavioral assessments to investigate the effect of citalopram on restricted repetitive&#xD;
      behaviors in people with autism spectrum disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Magnetic Resonance Imaging</measure>
    <time_frame>two 2-hr scans</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinicians Global Improvement Scale</measure>
    <time_frame>Upon study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Childrens Yale-Brown Obsessive Compulsive Scale</measure>
    <time_frame>Baseline, wks 2, 4, 8, endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with an Autism Spectrum Disorder receiving citalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals with an Autistic Spectrum Disorder receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Pill, 5-20mg once a day for twelve weeks</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Celexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill once a day for twelve weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory status (outpatient) at time of consent&#xD;
&#xD;
          -  Age 10-55 years&#xD;
&#xD;
          -  Clinical diagnosis of Autism Spectrum Disorder&#xD;
&#xD;
          -  IQ greater than or equal to 70&#xD;
&#xD;
          -  Score greater than 8 on Children's Yale-Brown Obsessive Compulsive Scale&#xD;
&#xD;
          -  Free of psychoactive medication for at least: one month for fluoxetine; two weeks for&#xD;
             other SSRIs and neuroleptics; and five days for stimulants prior to MRI scanning&#xD;
             [excepting stable doses (greater than three months duration) of anticonvulsant&#xD;
             medication for seizure disorder]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 10 years or greater than 55 years, at time of consent&#xD;
&#xD;
          -  Estimated IQ &lt; 70&#xD;
&#xD;
          -  Uncontrolled epilepsy (seizure within 6 months prior to consent)&#xD;
&#xD;
          -  4. Presence of medical conditions that might interfere with participation, or where&#xD;
             participation would be contraindicated&#xD;
&#xD;
          -  History of neurological injury: head trauma, poorly-controlled seizure disorder&#xD;
             (seizure within the preceding six months), stroke, prior neurosurgery, or under the&#xD;
             care of a neurologist or neurosurgeon as determined by interview&#xD;
&#xD;
          -  History of claustrophobia&#xD;
&#xD;
          -  Implanted or irremovable metal in the body (including certain tattoos and permanent&#xD;
             make-up)&#xD;
&#xD;
          -  Current pregnancy (as verified by testing prior to both initial dose administration of&#xD;
             citalopram or placebo and prior to magnetic resonance imaging) due to the risk that&#xD;
             may be associated with SSRI treatment and magnetic resonance imaging on fetal health&#xD;
&#xD;
          -  Medical contraindications to SSRI therapy as determined by history (including&#xD;
             induction of mania or hypomania during SSRI therapy, or known drug allergy)&#xD;
&#xD;
          -  Concomitant medication that would interfere with study participation&#xD;
&#xD;
          -  Prior history of citalopram treatment failure at appropriate doses and duration&#xD;
&#xD;
          -  Prior history of treatment failure to two previous SSRI trials at appropriate doses&#xD;
             and duration&#xD;
&#xD;
          -  Ongoing need for psychoactive medication other than study medication [excepting stable&#xD;
             doses (greater than three months duration) of anticonvulsant medication for seizure&#xD;
             disorder, or diphenhydramine (BenadrylÂ®)for sleep]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel S Dichter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC-Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>October 5, 2012</last_update_submitted>
  <last_update_submitted_qc>October 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Gabriel Dichter</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Restricted repetitive behaviors</keyword>
  <keyword>restricted interests</keyword>
  <keyword>Aspergers</keyword>
  <keyword>Autism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

